Ask AI

Empowering Collaboration in R/R MM: Amplifying the Patient’s Voice to Equip Community HCPs With Practical Strategies for Optimizing Bispecific Antibody Therapy

Enhance your understanding of available BCMA-directed bispecific antibodies used to treat relapsed/refractory multiple myeloma to improve patient outcomes through certified Medical Minute modules, an expert-authored ClinicalThought commentary, a podcast, and downloadable slides.

Share

Program Content

Activities

Transferring Bispecific Therapies to the Community
Bringing Bispecific Therapy Home: Best Practices for Transitioning Multiple Myeloma Patients from Academic to Community Care
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: December 24, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education

Supporters

Supported by an educational grant from Johnson & Johnson.

Johnson & Johnson